HFS
BMRN icon

Hantz Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hantz Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Buy
11,424
+86
+0.8% +$4.71K 0.01% 631
2026
Q1 		$640K Buy
11,338
+5,883
+108% +$343K 0.01% 580
2025
Q4 		$324K Buy
5,455
+3,900
+251% +$212K ﹤0.01% 696
2025
Q3 		$84K Buy
1,555
+499
+47% +$28.5K ﹤0.01% 1027
2025
Q2 		$58K Buy
1,056
+874
+480% +$51.5K ﹤0.01% 923
2025
Q1 		$13K Buy
182
+61
+50% +$4.1K ﹤0.01% 904
2024
Q4 		$8K Hold
121
– – ﹤0.01% 838
2024
Q3 		$9K Buy
121
+43
+55% +$3.59K ﹤0.01% 801
2024
Q2 		$6K Hold
78
– – ﹤0.01% 841
2024
Q1 		$7K Sell
78
-12
-13% -$1.07K ﹤0.01% 880
2023
Q4 		$9K Hold
90
– – ﹤0.01% 811
2023
Q3 		$8K Hold
90
– – ﹤0.01% 825
2023
Q2 		$8K Sell
90
-53
-37% -$4.99K ﹤0.01% 803
2023
Q1 		$14K Hold
143
– – ﹤0.01% 740
2022
Q4 		$15K Sell
143
-41
-22% -$3.85K ﹤0.01% 702
2022
Q3 		$16K Sell
184
-3
-2% -$267 ﹤0.01% 681
2022
Q2 		$15K Sell
187
-29
-13% -$2.31K ﹤0.01% 689
2022
Q1 		$17K Sell
216
-10,845
-98% -$907K ﹤0.01% 701
2021
Q4 		$977K Buy
11,061
+781
+8% +$64.4K 0.03% 369
2021
Q3 		$795K Buy
10,280
+2,379
+30% +$188K 0.03% 363
2021
Q2 		$659K Buy
7,901
+437
+6% +$34.6K 0.02% 370
2021
Q1 		$564K Sell
7,464
-509
-6% -$41.6K 0.02% 354
2020
Q4 		$699K Buy
7,973
+115
+1% +$9.12K 0.03% 312
2020
Q3 		$598K Buy
7,858
+732
+10% +$74.1K 0.03% 311
2020
Q2 		$879K Sell
7,126
-123
-2% -$12.2K 0.05% 279
2020
Q1 		$613K Buy
+7,249
New +$625K 0.04% 281

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hantz Financial Services's BMRN Position: Q2 2026 in Review

Hantz Financial Services increased its BioMarin Pharmaceuticals (BMRN) stake by 0.76% in Q2 2026, buying an estimated $4.71K and bringing the position to 11,424 shares worth $654K. The position accounts for 0.01% of the portfolio, ranked #631.

Hantz Financial Services first reported a position in BMRN in Q1 2020 and has held it in 26 quarters since. The position peaked at $977K in Q4 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Hantz Financial Services held 11,424 shares of BioMarin Pharmaceuticals worth $654K as of Q2 2026.
  • Hantz Financial Services bought 86 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • BioMarin Pharmaceuticals made up 0.01% of Hantz Financial Services's portfolio in Q2 2026, its #631 holding.
  • Hantz Financial Services first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Hantz Financial Services's BioMarin Pharmaceuticals position peaked at $977K in Q4 2021.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.